LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Inicio・Lista de Acciones・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Cerrado

4.7 -1.05

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.64

Máximo

4.84

Métricas clave
By Trading Economics
Ingresos	-10M -7.7M
Ventas	-10M 529K
Margen de beneficio	-1,463.516
Empleados	44
EBITDA	-10M -7.7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+48.31% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	18M 898M
Apertura anterior	5.75
Cierre anterior	4.7

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

3.255 / 3.365 Soporte y Resistencia

Arbutus Biopharma Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 mar 2026, 18:13 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mar 2026, 17:20 UTC

Noticias de Eventos Importantes

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mar 2026, 17:15 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mar 2026, 23:52 UTC

Charlas de Mercado

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mar 2026, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 23:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Correction to Crude Prices Market Talk on March 9

9 mar 2026, 23:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mar 2026, 23:08 UTC

Noticias de Eventos Importantes

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mar 2026, 23:07 UTC

Noticias de Eventos Importantes

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mar 2026, 21:29 UTC

Adquisiciones, fusiones, absorciones

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mar 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 mar 2026, 20:47 UTC

Noticias de Eventos Importantes

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mar 2026, 20:33 UTC

Noticias de Eventos Importantes

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mar 2026, 20:14 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mar 2026, 19:33 UTC

Noticias de Eventos Importantes

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mar 2026, 19:14 UTC

Charlas de Mercado

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mar 2026, 18:23 UTC

Charlas de Mercado

Noticias de Eventos Importantes

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mar 2026, 17:58 UTC

Adquisiciones, fusiones, absorciones

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mar 2026, 17:57 UTC

Adquisiciones, fusiones, absorciones

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mar 2026, 17:41 UTC

Noticias de Eventos Importantes

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mar 2026, 17:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mar 2026, 17:08 UTC

Charlas de Mercado

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mar 2026, 17:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 17:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp Esperado

Precio Objetivo

By TipRanks

48.31% repunte

Estimación a 12 meses

Media 7 USD 48.31%

Máximo 7 USD

Mínimo 7 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.